BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:
Alimera Sciences (ALIM - Get Report): 36-month results from phase III study of Iluvien in diabetic macular edema.
Earnings: Alkermes (ALKS), GlaxoSmithKline (GSK), Avanir Pharmaceuticals (AVNR), Merck (MRK), Vertex Pharmaceuticals (VRTX),
Adeona Pharmaceuticals (AEN) investor/analyst day.
Earnings: Seattle Genetics (SGEN), Rigel Pharmaceuticals (RIGL), Teva (TEVA), Feb. 9:
Earnings: Sanofi-Aventis (SNY) Feb. 10:
Earnings: Alexion Pharmaceuticals (ALXN), Cephalon (CEPH), Incyte Pharmaceuticals (INCY), MannKind (MNKD), Momenta Pharmaceuticals (NNTA). Feb 14-15:
BIO CEO & Investor Conference, New York City. Feb 15:
Expiration of Sanofi-Aventis' $69-a-share tender offer for Genzyme (GENZ). Feb. 16:
Earnings: Genzyme Feb. 17:
Exelixis (EXEL - Get Report): Presentation of updated cabozantinib (XL184) data in prostate cancer at ASCO GU symposium
Earnings: Biomarin Pharmaceuticals (BMRN), Acorda Therapeutics (ACOR) Feb. 22:
Earnings: Questcor Pharmaceuticals (QCOR) Feb 25:
Pfizer and Protalix Therapeutics (PLX - Get Report): FDA approval decision date for Uplyso in Gaucher's disease. Other potential February events
Idenix Pharmaceuticals (IDIX): FDA decision on lifting clinical hold on hepatitis C drugs IDX184 and IDX320.
Amylin Pharmaceuticals (AMLN), Alkermes, Eli Lilly (LLY): Start of a Bydureon Qt study. Source: Company reports, BioMedTracker.com --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.